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Abstract
Background: The term ‘‘atopic march’’ has been used to imply a natural progression of a cascade of symptoms from eczema
to asthma and rhinitis through childhood. We hypothesize that this expression does not adequately describe the natural
history of eczema, wheeze, and rhinitis during childhood. We propose that this paradigm arose from cross-sectional
analyses of longitudinal studies, and may reflect a population pattern that may not predominate at the individual level.
Methods and Findings: Data from 9,801 children in two population-based birth cohorts were used to determine individual
profiles of eczema, wheeze, and rhinitis and whether the manifestations of these symptoms followed an atopic march
pattern. Children were assessed at ages 1, 3, 5, 8, and 11 y. We used Bayesian machine learning methods to identify distinct
latent classes based on individual profiles of eczema, wheeze, and rhinitis. This approach allowed us to identify groups of
children with similar patterns of eczema, wheeze, and rhinitis over time. Using a latent disease profile model, the data
were best described by eight latent classes: no disease (51.3%), atopic march (3.1%), persistent eczema and wheeze (2.7%),
persistent eczema with later-onset rhinitis (4.7%), persistent wheeze with later-onset rhinitis (5.7%), transient wheeze (7.7%),
eczema only (15.3%), and rhinitis only (9.6%). When latent variable modelling was carried out separately for the two cohorts,
similar results were obtained. Highly concordant patterns of sensitisation were associated with different profiles of eczema,
rhinitis, and wheeze. The main limitation of this study was the difference in wording of the questions used to ascertain the
presence of eczema, wheeze, and rhinitis in the two cohorts.
Conclusions: The developmental profiles of eczema, wheeze, and rhinitis are heterogeneous; only a small proportion of
children (,7% of those with symptoms) follow trajectory profiles resembling the atopic march.
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Introduction
In the last two decades, the term ‘‘atopic march’’ has been
widely used to describe temporal changes in the prevalence of
childhood eczema, asthma, and allergic rhinitis reported in
epidemiological studies [1–4]. These studies led to the hypothesis
that the changes observed at the population level were a
consequence of the progression of a cascade of symptoms within
individual patients, starting with eczema, progressing to asthma,
and then to rhinitis (with a resolution of some of the early eczema
with increasing age) [1–3,5–9]. It has been proposed that the
observed temporal relationship between atopic diseases may help
earlier diagnosis, and may facilitate novel approaches to disease
prevention [10]. Practical clinical guidelines in both the US [11]
and the UK [12] refer to the existence of the atopic march, and
the leading UK guideline recommends that healthcare profession-
als inform parents that children with atopic eczema can often
develop asthma and/or allergic rhinitis. Indeed, this conceptual
framework has been used to design studies aiming to prevent the
development of airway inflammation and asthma in children who
were deemed to be at risk by virtue of having eczema and a family
history of atopic disease [13]. However, despite considerable effort
and investments in such studies, there is no evidence that targeting
children with eczema with an intervention designed to modify the
progression towards asthma is effective [14]. Of note, if atopic
march does not accurately describe the developmental profiles of
eczema, asthma, and rhinitis at an individual level, then stratifying
children in this way to asthma prevention programmes may not be
appropriate.
Most of the studies that associated early-life eczema with an
increased risk of subsequent asthma and allergic rhinitis used
cross-sectional data analyses (even within longitudinal studies), or
longitudinal analyses based on few time points, without taking into
account the time course of the development of symptoms within
individual children’s longitudinal profiles [2,5,15–21]. The exis-
tence of the atopic march has been questioned [22–24], with some
studies suggesting that there is heterogeneity between patients in
the chronology of the development of symptoms [25–27].
Children with early eczema who later develop asthma and rhinitis
may belong to a distinct phenotype, rather than representing the
typical progression of atopic diseases [27]. A recent review
concluded that despite apparent clear temporal association linking
eczema with progression to asthma and allergic rhinitis (and
plausible biological mechanisms to underpin such associations),
there is no definitive proof that atopic march is causal [4].
The emphasis on atopic march without robust evidence to
support this notion may hamper research into the underpinning
pathophysiology of atopy-related diseases. We propose that
eczema, wheeze, and rhinitis may appear to follow an atopic
march pattern if the prevalence or incidence of disease is
investigated cross-sectionally at a population level, but that this
may not best describe the trajectory of disease within most
individual patients. Recent developments in machine learning
provide new ways to capture the heterogeneity in longitudinal
patterns of distinct symptom categories within individual patients,
where conventional modelling techniques might over-aggregate
the underlying complexity [28]. Machine learning is a data-driven
approach to identify structure within the data using unsupervised
learning of latent variables. It is used commonly by computer
scientists for problem-solving in many other fields, and is
increasingly used to disaggregate complex disease phenotypes in
respiratory medicine and allergy [29–32]. In machine learning,
latent variable modelling allows us to hypothesize the existence of
an underlying trait that is not directly observed or measured, but
whose presence can be indirectly inferred by the existence of
different observed patterns of symptoms. A latent variable is a
hypothetical construct used to describe generalised manifestations
that cannot be directly measured, but whose presence may be
inferred based on a set of observable characteristics or features
(e.g., similar patterns of responses to a series of questions). These
variables are widely used in the psychiatric literature to classify
varying severity of constructs, such as ‘‘intelligence’’, ‘‘depression’’,
and ‘‘autism’’, that cannot be directly measured [33,34] or discrete
latent classes or categories of latent variables such as ‘‘severe
depression’’, ‘‘mild depression’’, and ‘‘intermediate depression’’.
Within the context of the current study, machine learning may
facilitate better understanding of how the relationships between
symptom transitions can be generalised to identify patterns of
symptoms within children. We hypothesize that the atopic march
is an imposed paradigm that does not adequately describe the
natural history of eczema, wheeze, and rhinitis during childhood,
and that a data-driven approach may help us to identify
developmental profiles of symptoms over time by uncovering the
latent structure in the data. To address this hypothesis, we used
machine learning techniques to model the development of eczema,
wheeze, and rhinitis during childhood in two large population-
based birth cohorts, taking into account longitudinal changes
within individual children.
Methods
Design, Setting, Participants, and Data Sources
We studied two population-based birth cohorts from the UK:
the Avon Longitudinal Study of Parents and Children (ALSPAC)
[35] and the Manchester Asthma and Allergy Study (MAAS) [36].
Both studies were approved by local research ethics committees.
Written informed consent was obtained from all parents.
Participants were recruited prenatally, and followed prospectively.
We administered validated questionnaires to collect information
on parentally reported symptoms at review clinics at five
comparable follow-up points (ages 1, 3, 5, 8, and 11 y). We
included children who had data available for at least two time
points for each symptom.
Manchester Asthma and Allergy Study. MAAS was a
population-based birth cohort study that included the maternity
catchment area of Wythenshawe and Stepping Hill Hospitals (50
square miles of South Manchester and Cheshire), a stable mixed
urban-rural population. All pregnant women were screened for
eligibility at antenatal visits (8th–10th week of pregnancy) between
1 October 1995 and 1 July 1997. Of the 1,499 women and their
partners who met the inclusion criteria (,10 wk of pregnancy,
maternal age.18 y, questionnaire and skin test data available for
both parents), 288 declined to take part in the study, and 27 were
lost to follow-up between recruitment and childbirth. A total of
1,184 participants had at least some evaluable data, and 1,136
participants had data for at least two time points.
Children attended review clinics at ages 1, 3, 5, 8, and 11 y.
Validated American Thoracic Society–Division of Lung Disease
(ATS-DLD-78) [37] (age 1 and 3 y) and International Study of
Asthma and Allergies in Childhood (ISAAC) [38] (age 5, 8, and 11 y)
questionnaires were interviewer-administered to determine paren-
tally reported history of wheeze, eczema, and rhinitis, and treatments
received. Atopic sensitisation was ascertained by skin prick testing for
common inhalant and food allergens [29]. We also extracted all data
from electronic and paper-based primary care medical records,
including topical corticosteroid prescriptions for eczema.
Avon Longitudinal Study of Parents and
Children. ALSPAC was a population-based birth cohort study
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in Avon, United Kingdom. ALSPAC was additionally approved
by the ALSPAC Law and Ethics Committee. ALSPAC recruited
14,541 pregnant women between 1 April 1991 and 31 December
1992. A total of 8,665 participants had data for at least two time
points.
Children attended review clinics at ages 1.5, 3.5, 4.5, 8.6, and
10.7 y. A modified ISAAC questionnaire [38] was administered to
determine parentally reported history of wheeze, eczema, and
rhinitis and treatments received. Skin prick testing was carried out
at the follow-up at age 8.6 y.
Definition of Variables
Current eczema. This variable was defined as a positive
answer to the question ‘‘Has your child had an itchy rash that
comes and goes in the last 12 months?’’ [38] (ALSPAC, all time
points; MAAS, ages 5, 8, and 11 y) or ‘‘Has your doctor ever told
you that your child has eczema?’’ [37] (MAAS, age 1 and 3 y).
Current wheeze. This variable was defined as a positive
answer to the question ‘‘In the last 12 months has he/she had any
periods when there was wheezing or wheezing with whistling on
his/her chest when he/she breathed?’’ (ALSPAC) or ‘‘Has your
child had wheezing or whistling in the chest in the last 12
months?’’ (MAAS).
Current rhinitis. This variable was defined as a positive
answer to the question ‘‘In the past 12 months, has your child had
a problem with sneezing or a runny or blocked nose when he/she
did not have a cold or the flu?’’ [38] (ALSPAC and MAAS, ages 5,
8, and 11 y) or ‘‘Has your doctor ever told you that your child has
hay fever or allergic rhinitis?’’ [37] (MAAS, age 1 and 3 y).
Current asthma. This variable was defined as the presence
of any two of the following three features: current wheeze, current
use of asthma medication, or physician-diagnosed asthma ever.
Atopic sensitisation. We defined sensitisation as a wheal
diameter 3 mm greater than the negative control to at least one
allergen.
Moderate/severe eczema. This variable was defined in
MAAS as parentally reported eczema (questionnaires) and
confirmed topical corticosteroid prescriptions for eczema by
primary care physician (medical records).
Statistical Analysis
Longitudinal data were jointly modelled across the two cohorts,
and separately for each cohort. We used a Bayesian machine
learning modelling framework [28] with an expectation propaga-
tion algorithm [39] for approximate inference to identify distinct
latent classes based on individual changing disease profiles of
eczema, wheeze, and rhinitis. We hypothesized that these different
patterns represent the existence of distinct latent classes. All
machine learning models were specified using Infer.NET (http://
research.microsoft.com/infernet) [40].
In order to capture disease heterogeneity and encapsulate
possible different patterns of symptom progression in individual
children over time, we investigated three models. We first used two
Markov chain probability models that assumed that the probabil-
ity of an event depends on the disease state at the previous time
point. These models allowed us to test the assumption that
transitions or the sequence from one disease state to another follow
the atopic march profile. For each of the models, we assumed a
discrete time model at time steps where data were available (i.e., at
ages 1, 3, 5, 8, and 11 y).
Model 1. Model 1 assumed that eczema, wheeze, and rhinitis
profiles follow independent disease profiles over time that are
linked by a single multinomial latent variable. This model assumed
that the transition of acquiring, retaining, or remitting each disease
followed an independent Markov chain of events, i.e., the
probability of each disease depends on the previous state of that
particular disease. In other words, the probability of having (or
not having) eczema at time t is conditional on the probability of
eczema at time t21, which in turn is conditional on the
probability of eczema at time t22, with identical transition
probability assumptions for the probability of wheeze and rhinitis.
These three independent transition probability chains were
governed by three latent disease classes, represented as an
eczema class, a wheeze class, and a rhinitis class. Binary responses
are linked via a probit link function. Figure 1 summarises the
model specification.
Model 2. Model 2 was the atopic march model, which
assumed that the transition states proposed by the atopic march
give a more optimal description of the data. This model assumed
explicit probability transitions of progression from one disease to
another (e.g., eczema at time t predicts wheeze at time t+1;
Figure 2). This model allows eczema at time t21 to condition the
probability of wheeze at time t, and wheeze at time t to condition
the probability of rhinitis at time t+1. These transitions resemble
the progression hypothesized by the atopic march of symptoms,
where eczema predicts later predisposition to wheeze, which in
turn predicts later onset of rhinitis. Patterns of transition from one
disease state to another were governed by a multinomial latent
variable. Binary responses are linked via a probit link function.
Figure 2 summarises the conditional probabilities that link these
transitions for the model specification.
Model 3. We specified a third model, a latent disease profile
model, that assumed an unconstrained transition matrix. This
model was specified as a longitudinal probit regression model for
the repeated dichotomous variable representing the answer to the
question ‘‘Has the child had [a particular symptom] within the
past 12 months?’’ where the symptoms were eczema, wheeze, and
rhinitis. For each child, we assumed a uniform Dirichlet prior
distribution with equal probability assignment to each latent class.
The hyperparameter for the prior is a vector of pseudocounts or
constants representing the ‘‘prior’’ number of observations in each
of the n classes, and the posterior is estimated using expectation
propagation. The tuning of hyperparameters is performed using
posterior model parameters for each step of the inference
algorithm using Bayesian inference. Model evidence (marginal
likelihood) was tuned using posterior model parameters for each
step of the inference algorithm derived by integrating out over all
variables. We have specified a flat Gaussian prior on the variance,
with a mean of zero and a precision of one.
This model assumes that other than random temporal
fluctuation, each child’s joint pattern of eczema, wheeze, and
rhinitis can be explained by their belonging to a particular disease
class profile. This model makes no constraints on (1) the structure
of transitions within and between different symptoms over time or
(2) the progression from one symptom to another. The conditional
transition probabilities are evaluated and assumed to be indepen-
dent. Figure 3 summarises this model.
Note that for these models, t+1 refers to the next time step at
which data were collected. So, for example, if t is age 3 y, t+1
would be age 5 y. Likewise, t21 refers to the previously
observed time step. So, for example, if t is age 11 y, t21 would
be age 8 y.
Each of these three models was fitted on the full, combined
dataset across both cohorts. In each of these three models, we
assumed that each child belongs to one of n latent classes; the
number and size of classes were not known a priori. Children
belonging to the same class are similar with respect to the observed
pattern of observations over time. These homogenous classes of
Developmental Profiles of Eczema, Wheeze, and Rhinitis
PLOS Medicine | www.plosmedicine.org 3 October 2014 | Volume 11 | Issue 10 | e1001748
children that we identified were assumed to come from the same
probability distributions. For each child, we calculated the
posterior probability of belonging to each of the latent classes,
and assigned children to their highest probability class. We
compared the models using model evidence, a measure of model
goodness-of-fit, to identify the most parsimonious model [41].
Figure 1. Graphical representation of the independent Markov chain model where transitions within each symptom are assumed to
be independent (Model 1). Shaded circles represent observed variables, and unshaded circles represent latent variables to be inferred. Symptoms
are joined together by a latent class disease profile.
doi:10.1371/journal.pmed.1001748.g001
Figure 2. Graphical representation of the Markov chain model allowing transition probabilities across symptoms to follow an
atopic march progression of symptoms (Model 2). Shaded circles represent observed variables, and unshaded circles represent latent variables
to be inferred. Symptoms are joined together by a latent class disease profile.
doi:10.1371/journal.pmed.1001748.g002
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In order to assess the possible effect of Lindley’s paradox, which
may occur when model evidence is mostly determined by the prior
as opposed to the likelihood of the data, we specified a range of
priors, setting the pseudocounts to 1/n, 2/n, 1, and 2.
Bayesian data analysis consists of three principle stages for
statistical inference: first, specifying a prior or quantifying a
hypothesis; second, assessing statistical modelling on the data that
we have at hand; and third, updating our prior knowledge with the
analysis of the data. For all three models, the uniform Dirichlet
prior that we used allows us to assume that each child has an equal
probability (1/n) of belonging to n classes, where we specified n to
range from 2 to 15 classes. Using a Dirichlet prior is equivalent to
an agnostic approach to our data analysis, where we assume that
each child has an equal probability of belonging to each class and
also that the number of children within each class is equal. For
each child, we assumed a uniform Dirichlet prior distribution with
equal probability assignment to each latent class. For the interested
reader, the book Bayesian Data Analysis [42] by Gelman et al.
provides insight on choosing uniform priors, and the book Pattern
Recognition and Machine Learning [43] provides a more in-depth
discussion of unsupervised learning methods such as the ones
presented in our models.
We also investigated the longitudinal profiles using current
asthma rather than wheeze.
In order to investigate whether similar profiles exist among
children who may be classified as having moderate/severe eczema,
in the MAAS cohort we carried out additional analysis excluding
children with mild eczema. We defined mild eczema as parentally
reported eczema, but no physician-prescribed topical corticosteroid.
Longitudinal analysis of the trajectories of atopic sensitisation in
different latent classes in the MAAS population was performed
using generalised estimating equations (Stata 12, StataCorp,
College Station, Texas).
Results
Participant Flow
We included a total of 9,801 children (8,665 from ALSPAC,
1,136 from MAAS). Characteristics of the study populations,
including the prevalence of wheeze, eczema, and rhinitis at each
time point, are presented in Table 1 and Figure 4. There were
similar cross-sectional patterns across the two cohorts, with a
steady decrease in wheeze and eczema with increasing age,
whereas the prevalence of rhinitis increased with age.
Latent Disease Profiles Identified
Comparing model evidence, Model 1 (which assumed that
disease transitions are independent) gave a better fit than Model 2
(which explicitly assumed atopic march transitions). However,
these two models did not reach stable model convergence and
were therefore not evaluated further. Stable model convergence
was achieved in Model 3 (latent disease profile model); the optimal
solution that best described the data was a model that inferred
eight latent classes (Table S1). Posterior probabilities of class
membership were generally high (Table S2). Based on our
interpretation of their characteristics in relation to patterns of
eczema, wheeze, and rhinitis during childhood (Figure 5), we
assigned the following labels to the latent eight classes.
No disease (n=5,023, 51.3%). Children in this class had a
low probability of eczema, wheeze, and rhinitis.
Atopic march (n=302, 3.1%). Children in this class had a
high probability of eczema from infancy to age 11 y. The
probability of wheeze increased with time. For rhinitis, the
probability increased from zero at age 1 y to almost 100% by age
8 y. Eczema developed first, followed by wheeze, and then rhinitis;
however, there was little evidence of resolution of eczema by age
11 y.
Figure 3. Graphical representation of the latent disease profile model taking into account the co-occurrence of symptoms at each
time point (Model 3). Shaded circles represent observed variables, and unshaded circles represent latent variables to be inferred. Symptoms are
joined together by a latent class disease profile.
doi:10.1371/journal.pmed.1001748.g003
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Persistent eczema and wheeze (n=266, 2.7%). There was
similar probability of wheeze and eczema throughout childhood,
likely as co-morbidities, with a low probability of rhinitis
throughout childhood.
Persistent eczema with later-onset rhinitis (n=456,
4.7%). The prevalence of eczema increased steadily from
,70% in early life to 95% at age 5 y, with little resolution to
age 11 y. The probability of rhinitis increased to almost 100% by
Table 1. Characteristics of the two cohorts.
Characteristic MAAS Cohort ALSPAC Cohort Joint MAAS and ALSPAC Cohort
n/Total Percent n/Total Percent n/Total Percent
Gender (Female) 617/1,136 54.3 4,212/8,665 48.61 4,829/9,801 49.3
Eczema
Age 1 y 383/1,077 35.6 2,263/8,328 27.2 2,646/9,405 28.1
Age 3 y 355/1,061 33.5 1,872/8,165 22.9 2,227/9,226 24.1
Age 5 y 340/1,050 32.4 1,974/8,080 24.4 2,314/9,130 25.3
Age 8 y 285/1,027 27.8 1,542/8,163 19.5 1,827/9,190 19.9
Age 11 y 216/924 23.4 1,252/7,047 17.8 1,468/7,971 18.4
Wheeze
Age 1 y 300/1,087 27.6 2,210/8,276 26.7 2,510/9,363 26.8
Age 3 y 257/1,095 23.5 1,392/8,168 17.0 1,649/9,263 17.8
Age 5 y 238/1,056 22.5 1,496/8,130 18.4 1,734/9,186 18.9
Age 8 y 185/1,024 18.1 897/7,182 12.5 1,082/8,206 13.2
Age 11 y 173/916 18.9 841/6,958 12.1 1,014/7,874 12.9
Rhinitis
Age 1 y 8/943 0.9 8/943 0.9
Age 3 y 49/1,075 4.6 49/1,075 4.6
Age 5 y 292/1,039 28.1 197/8,421 2.3 489/9,460 5.2
Age 8 y 297/1,027 28.9 1,438/6,513 22.1 1,128/7,540 23.0
Age 11 y 321/927 34.6 1,271/6,953 18.3 1,592/7,880 20.2
Sensitisation
Age 1 y 55/484 11.4
Age 3 y 222/970 22.9
Age 5 y 289/952 30.4
Age 8 y 314/927 33.9 874/5,624 15.5 1,188/6,551 18.1
Age 11 y 280/795 35.2
doi:10.1371/journal.pmed.1001748.t001
Figure 4. Prevalence of wheeze, eczema, and rhinitis over cross-sectional time points in the ALSPAC and MAAS cohorts.
doi:10.1371/journal.pmed.1001748.g004
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age 8 y. These children had a low probability of wheeze
throughout childhood.
Persistent wheeze with later-onset rhinitis (n=556,
5.7%). This class was characterised by a high probability of
wheeze throughout childhood, with increasing probability of
rhinitis to almost 100% by age 11 y. Probability of eczema was
low, declining steadily to age 11 y.
Transient wheeze (n=755, 7.7%). Children in this class
had a high probability of wheeze within the first 5 y, with
remission by age 8 y, and a very low probability of eczema and
rhinitis throughout childhood.
Eczema only (n=1,506, 15.3%). High probability of
eczema throughout life, peaking at ,80% at age 5 y, then
declining steadily to a 50% probability at age 11 y.
Rhinitis only (n=936, 9.6%). Children in this class had
increasing probability of rhinitis from age 5 to 11 y, but no wheeze
or eczema.
Similar results were obtained when modelling was carried out
separately for the MAAS and ALSPAC cohorts (Figures 6 and 7).
Latent variable modelling using ‘‘current asthma’’ instead of
‘‘current wheeze’’ gave similar profiles (Figure S1).
Changing prior parameters by setting the pseudocounts to 1/n,
2/n, 1, and 2 gave consistent model evidence (Table S3) and
results, identifying a small group of children who followed profiles
similar to the atopic march.
Latent Classes and Gender
There were no significant gender differences in the classes no
disease, persistent eczema and wheeze, and persistent eczema with
later-onset rhinitis (Table 2). The eczema only class contained a
higher proportion of girls (57.4% versus 42.6%, p,0.001). In
contrast, in all other classes there were more boys than girls (p,
0.001), most notably in the atopic march (60.9% versus 39.1%)
and persistent wheeze with later-onset rhinitis (62.8% versus
37.2%) classes.
Trajectories of Sensitisation in Different Classes
By age 11 y, 35.2% of children in MAAS were sensitised,
increasing from 11.4% at age 1 y (Table 1). The trajectories of
sensitisation in different classes are presented in Figure 8, and
superimposed on different classes in Figure S2. For the classes
persistent eczema and wheeze, persistent wheeze with later-onset
Figure 5. Distinct disease profile classes. Using Bayesian machine learning joint modelling of eczema, wheeze, and rhinitis across two
population-based birth cohorts, we identified eight distinct disease profile classes. The number of children and the proportion of the study
population are indicated for each class. Plots indicate longitudinal trajectories of wheeze, eczema, and rhinitis within each class.
doi:10.1371/journal.pmed.1001748.g005
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rhinitis, and rhinitis only, the trajectories of sensitisation were very
similar (p.0.2). Children in the rhinitis only class had a significantly
higher risk of sensitisation than those in the eczema only class (odds
ratio [OR]=2.16, 95% confidence interval (CI) 1.48–3.16, p,
0.001). There was no significant difference in the probability of
sensitisation between children in the classes transient wheeze and no
disease (p=0.28), whilst children in all other classes were at an
increased risk of sensitisation compared to the no disease class
(Table S4). Children in the atopic march class were at the highest
risk of sensitisation (OR=21.92, 95% CI 13.56–35.42, p,0.001)
(Table S4). Analysis using data on sensitisation from both MAAS
and ALSPAC at age 8 y showed similar trends (Table 3), with
children in the atopic march class having significantly higher risk of
sensitisation than all other groups (p,0.001).
Latent Disease Profiles among Children with Moderate/
Severe Eczema
Within the MAAS cohort (for which we had relevant data to
enable indirect ascertainment of eczema severity), we carried out
further analyses excluding children with mild eczema to investigate
disease profiles among children with moderate/severe eczema. We
excluded data from 88 children with parentally reported eczema at
age 1 or 3 y, but no general practitioner prescription for topical
corticosteroids during this time (and therefore assumed to have
mild eczema) and from 97 children with parentally reported
eczema but missing general practitioner prescription data (so
severity could not be confirmed). A total of 102 children had
missing data on eczema at ages 1 and 3 y. We identified six classes.
Based on our interpretation of their characteristics (Figure S3), we
have labelled these classes as follows.
No disease (n=473, 52.7%). Children in this class had a
low probability of eczema, wheeze, and rhinitis.
Atopic march (n=63, 7.0%). Children in this class had a
high probability of eczema from infancy to age 11 y. The
probability of wheeze increased with time. For rhinitis, the
probability increased from 0% at age 1 to ,80% by age 11 y.
Eczema developed first, followed by wheeze, and then rhinitis;
however, there was little evidence of resolution of eczema by age
11 y.
Figure 6. Distinct disease profile classes in MAAS. Bayesian machine learning joint modelling of eczema, wheeze, and rhinitis for the MAAS
cohort. We identified eight distinct disease profile classes that best described the data. Class 1, no disease; class 2, atopic march; class 3, persistent
eczema and wheeze; class 4, persistent eczema with later-onset rhinitis; class 5, persistent wheeze with later-onset rhinitis; class 6, transient wheeze;
class 7, eczema only; class 8, rhinitis only.
doi:10.1371/journal.pmed.1001748.g006
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Figure 7. Distinct disease profile classes in ALSPAC. Bayesian machine learning joint modelling of eczema, wheeze, and rhinitis for the ALSPAC
cohort. We identified eight distinct disease profile classes that best described the data. Class 1, no disease; class 2, atopic march; class 3, persistent
eczema and wheeze; class 4, persistent eczema with later-onset rhinitis; class 5, persistent wheeze with later-onset rhinitis; class 6, transient wheeze;
class 7, eczema only; class 8, rhinitis only.
doi:10.1371/journal.pmed.1001748.g007
Table 2. Gender distribution in different classes.
Class Number Class Female, N (Percent) Male, N (Percent) p-Value
1 No disease 2,456 (48.9) 2,567 (51.1) Baseline
2 Atopic march 118 (39.1) 184 (60.9) 0.001
3 Persistent eczema and wheeze 128 (48.1) 138 (51.9) 0.81
4 Persistent eczema with later-onset rhinitis 223(48.9) 233 (51.1) 0.99
5 Persistent wheeze with later-onset rhinitis 207 (37.2) 349 (62.8) ,0.001
6 Transient wheeze 313 (41.5) 442 (58.5) ,0.001
7 Eczema only 864 (57.4) 642 (42.6) ,0.001
8 Rhinitis only 422 (45.1) 514 (54.9) 0.032
Total 4,731 (48.3) 5,070 (51.7)
doi:10.1371/journal.pmed.1001748.t002
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Transient early eczema and wheeze (n=71, 7.9%). Ec-
zema was present at age 1 and 3 y, and then the probability of
eczema diminished at age 5 y, with no eczema by age 11 y. These
children also had a decreasing probability of wheeze over time,
with little rhinitis.
Wheeze/wheeze with later-onset rhinitis (n=92,
10.3%). Children in this class had a high probability of wheeze
throughout childhood, with a ,40% probability of rhinitis by age
5 y.
Eczema/eczema with later-onset rhinitis (n=94,
10.3%). Children in this class had a high probability of eczema
throughout childhood, with a ,60% probability of rhinitis by age
11 y.
Rhinitis only (n=104, 11.6%). Children in this class had
increasing probability of rhinitis from age 5 to 11 y, but no wheeze
or eczema.
These classes were strongly associated with those identified
using joint modelling of all data, including children with mild
eczema (p,0.0001; Table S5). The exception was a new class of
children with transient early eczema and no other symptoms. Of
note, a similar class was identified when we analysed data from the
MAAS cohort only (Figure 6, class persistent eczema and wheeze).
Of note, in the model excluding children with mild eczema, 46.1%
of children developed wheeze or rhinitis independent of eczema
(classes wheeze/wheeze with later-onset rhinitis and rhinitis only).
This proportion is similar to the results of the model including all
children with eczema, in which 45.6% of children developed
wheeze or rhinitis independent of eczema.
We note that because of the smaller number of children, the
model excluding children with mild eczema is poorer at
distinguishing (1) between children with wheeze with later-onset
rhinitis and children with wheeze only (57.6% of these children
Figure 8. Proportion of children sensitised in each latent disease profile.
doi:10.1371/journal.pmed.1001748.g008
Table 3. Sensitisation distribution in different classes (data on sensitisation from both MAAS and ALSPAC cohorts at age 8 y).
Class Number Class Not Sensitised, N (Percent) Sensitised, N (Percent) OR (95% CI) p-Value
1 No disease 3,036 (93.0) 228 (7.0) Baseline Baseline
2 Atopic march 62 (29.0) 152 (71.0) 32.6 (23.6–45.2) ,0.001
3 Persistent eczema and wheeze 136 (70.1) 58 (29.9) 5.7 (4.1–7.9) ,0.001
4 Persistent eczema with later-onset
rhinitis
159 (47.5) 176 (52.5) 14.7 (11.4–19.0) ,0.001
5 Persistent wheeze with later-onset
rhinitis
203 (53.8) 174 (46.2) 11.4 (9.0–14.6) ,0.001
6 Transient wheeze 439 (90.1) 48 (9.9) 1.5 (1.0–2.0) 0.024
7 Eczema only 869 (86.3) 138 (13.7) 2.1 (1.7–2.6) ,0.001
8 Rhinitis only 458 (68.2) 184 (31.8) 5.3 (4.3–6.7) ,0.001
Total 5,265 (81.9) 1,162 (18.1)
doi:10.1371/journal.pmed.1001748.t003
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were identified as wheeze with later-onset rhinitis and 40.2% were
identified as wheeze only in the original model) and (2) between
children with eczema only and children with eczema with later-
onset rhinitis (55.3% of these children were identified as eczema
with later-onset rhinitis and 40.4% as eczema only in the original
model).
The data suggest that including children with mild eczema
resulted in a greater certainty in class assignment.
Discussion
By jointly modelling longitudinal data from two independent
population-based birth cohorts, we have identified eight different
classes describing the temporal trajectories of eczema, wheeze, and
rhinitis during childhood. Less than 7% of children with symptoms
followed a trajectory profile resembling the atopic march, in which
early eczema and wheeze were followed by rhinitis. In contrast to
the commonly held view [2,6,7], we saw little evidence of
resolution of eczema in this class. The remaining six disease
classes were generally characterised by the presence of only one or
two of the three symptoms, indicating that more than 90% of
children with symptoms commonly associated with atopy in
childhood do not follow the widely perceived trajectory of the
atopic march. Furthermore, highly concordant patterns of
sensitisation over time were associated with very different profiles
of symptoms; for example, the classes persistent eczema and
wheeze, persistent wheeze with later-onset rhinitis, and rhinitis
only had similar temporal patterns of sensitisation. Conversely, for
the three classes characterised by persistence of wheeze—atopic
march, persistent eczema, and wheeze, persistent wheeze with
later-onset rhinitis—patterns of sensitisation were different, as
were patterns of co-morbid eczema and rhinitis. This may suggest
uncoupling of the mechanisms leading to atopic sensitisation and
those leading to symptoms, and is consistent with the recent
discovery of different phenotypes of atopy characterised by
different patterns of IgE responses to allergens (both over time
and to different individual allergens) that differ in their associations
with clinical symptoms [29,30,44]. Future work may be carried out
to investigate whether there are underlying biological and genetic
markers associated with these potentially distinct mechanisms.
Limitations and Strengths
The questions that we used in the two cohorts contained small
differences in the wording (e.g., in MAAS, the wheezing question
asked about ‘‘wheezing or wheezing with whistling in the chest’’,
whereas in ALSPAC, the question asked about ‘‘wheezing with
whistling on his/her chest when he/she breathed’’). However,
these differences were small, and it is unlikely that they have
affected the results.
The differences in the prevalence of rhinitis between the two
cohorts may be of concern. However, it is striking that when we
modelled the data separately for each cohort, although the
prevalence of rhinitis was higher in MAAS compared to ALSPAC,
the results indicated similar latent profiles, suggesting consistent
patterns of symptoms across the two populations.
Data on confirmed food allergy were not available from early
life in either cohort, and was therefore not included in the model.
Sensitisation data were available for ALSPAC at only one time
point (age 8 y); we therefore used data only from MAAS to
compare longitudinal patterns of sensitisation across the latent
classes, and the analysis of probabilities of sensitisation across the
two cohorts was limited to age 8 y.
We acknowledge that the definition of eczema that we used in
our models is based on parental reporting using validated
questionnaires (as in most other epidemiological studies), and that
this may lead to overestimation of the true prevalence. For the
MAAS cohort, we extracted all data from the primary care
medical records, which enabled comparison between physician-
diagnosed and parentally reported eczema. For ,85% of children
whose parents reported eczema, eczema was confirmed in the
primary care records, indirectly suggesting that overestimation of
the prevalence of eczema is unlikely.
One of the major strengths of this study is the ability to
disambiguate the temporal structure of disease profiles, thus
allowing us to identify groups of children with similar patterns of
the onset and progression of eczema, wheeze, and rhinitis over
time. It is striking that when we modelled the data separately for
each cohort, although there was a higher prevalence of rhinitis in
MAAS compared to ALSPAC, the results indicated similar latent
profiles, suggesting consistent evidence across the two populations.
The joint modelling of both MAAS and ALSPAC data gave
stronger evidence for these patterns. A further advantage of joint
modelling is the ability to borrow strength using complex machine
learning models, and obtain better statistical models to predict
expected profiles based on the presence of symptoms across the
two cohorts. For example, this approach enabled learning about
early-life rhinitis parameters in ALSPAC (where these data were
absent) from the MAAS data. Similarly, the larger sample size in
ALSPAC, when combined with MAAS, gave a greater resolution
in identifying patterns of disease profiles and assigning children to
different classes with less uncertainty.
Interpretation
When we present the prevalence data from each time point
cross-sectionally in our two cohorts (Figure 9), the profile appears
strikingly similar to the traditional concept of atopic march [7]. It
is clear that this traditional approach reflects patterns at the
population level, rather than the natural covariance of symptoms
within individuals’ life courses. We have applied computationally
intensive techniques of machine learning coupled with Bayesian
inference to model the data longitudinally, thereby allowing the
identification of a latent structure within the data that may better
reflect the individual life course (as opposed to changes in
prevalence at the population level). These approaches allowed us
to construct customised models for longitudinal data in order to
explicitly incorporate uncertainty and investigate hypotheses
regarding the co-occurrence of eczema, wheeze, and rhinitis over
time. By explicitly modelling the assumptions underlying the
atopic march (that the profile of this march of symptoms may
follow a chronological manifestation of eczema, wheeze, and then
rhinitis), we found that this model does not capture patterns in the
data as well as a model in which we assumed that eczema, wheeze,
and rhinitis follow independent trajectories. A recent review has
challenged the lack of robust evidence for inferring that eczema is
causally linked to asthma and rhinitis [4]. Our results suggest that
the relationship between eczema, wheeze, and rhinitis is not
causal, but can be explained by an underlying latent (non-
observed) disease status within the population, whose structure we
were able to infer by investigating individual longitudinal disease
profiles. We propose that eczema, wheeze, and rhinitis are all
common and so co-exist, but mostly as independent entities, each
associated to a greater or lesser degree with atopic sensitisation.
Our results show that although there is a group of children with
trajectories similar to the atopic march paradigm, this group
comprises approximately one child in every 20 with symptoms. Of
note, a striking characteristic of this class is a very strong
association with atopy.
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A recent study provided evidence in support of atopic march in
relation to early-life mild eczema in the general population [3]. We
acknowledge that atopic march may be associated with severe/
moderate eczema, and that the likely inclusion of very mild
eczema in our analysis may have skewed the results. To address
this concern, within the MAAS cohort (in which we have relevant
data to indirectly ascertain eczema severity), we carried out further
analyses excluding children with mild eczema to investigate disease
profiles among children with moderate/severe eczema (and those
without eczema). We identified similar classes with profiles similar
to those identified when using joint modelling of all the data. It is
of note that even when children with mild eczema were excluded
from the analysis, the atopic march class accounted for only 5.8%
of the general population.
Four of the classes included eczema as a characteristic feature
(atopic march, persistent eczema and wheeze, eczema with later-
onset rhinitis, and eczema only). It is important to note that by far
the largest of these was the eczema only class (15.4% of the total
population, including 60% of children within classes in which
eczema was a characteristic feature). In this class (uniquely
characterised by female predominance), eczema occurred gener-
ally without wheeze or rhinitis, suggesting that most children with
early eczema continue having eczema only, and do not progress to
develop co-morbidities. In the persistent eczema and wheeze class,
eczema and wheeze occurred as co-morbidities (i.e., wheeze did
not follow after eczema). Only in the atopic march class
(accounting for only 12% of children assigned to a class where
eczema was a characteristic feature) was there any suggestion that
eczema may precede wheeze. This would argue against the
relevance of the atopic march for most children with eczema.
Thus, using eczema as the indicator of subsequent risk of asthma,
and assigning ‘‘preventative’’ measures to this group [13], is
flawed, given that most children with early eczema will not
develop asthma. The results of our study emphasise the need for
clinicians to acknowledge the heterogeneity of patterns of
‘‘allergic’’ diseases and to communicate to parents the uncertainty
inherent in predicting the development of new symptoms or
resolution of existing ones.
Conclusions
Our results provide evidence that suggests that the develop-
mental profiles of eczema, wheeze, and rhinitis are heterogeneous,
and that only a small proportion of children follow a trajectory
profile similar to that of the atopic march.
Supporting Information
Figure S1 Bayesian machine learning joint modelling of
eczema, asthma, and rhinitis for both the ALSPAC and
MAAS cohorts.We identified eight distinct disease profile classes
that best described the data.
(DOCX)
Figure S2 Profiles of sensitisation in the MAAS cohort
across latent classes identified via jointly modelling data
from both the ALSPAC and MAAS cohorts.
(DOCX)
Figure S3 Bayesian machine learning joint modelling of
eczema, wheeze, and rhinitis for the MAAS cohort,
excluding children with mild eczema.
(DOCX)
Table S1 Model evidence for different numbers of
inferred latent classes. Evidence was assessed on 100 random
samples of hold-out data. Higher evidence indicates better model
fit. The optimal solution was a model that inferred eight latent
disease profiles. Model convergence was assumed when model
evidence remained stable for 100 consecutive iterations.
(DOCX)
Table S2 Posterior probabilities of class membership.
This is the conditional probability that a child is assigned to a particular
(predicted) class given their actual assigned class membership.
(DOCX)
Figure 9. Profile plot showing cross-sectional change in prevalence of eczema, wheeze, and rhinitis in the ALSPAC and MAAS birth
cohorts.
doi:10.1371/journal.pmed.1001748.g009
Developmental Profiles of Eczema, Wheeze, and Rhinitis
PLOS Medicine | www.plosmedicine.org 12 October 2014 | Volume 11 | Issue 10 | e1001748
Table S3 Model evidence for different numbers of
inferred latent classes with different priors. This table
compares priors where the number of pseudocounts is set to from
1/n up to 2 to investigate whether setting different priors
influences model evidence.
(DOCX)
Table S4 Odds ratios with 95% confidence intervals for
the association of latent disease profile classes with
longitudinal sensitisation in the MAAS cohort. Models
were adjusted for age.
(DOCX)
Table S5 Confusion matrix showing association be-
tween classes obtained excluding and including children
with mild eczema in the MAAS cohort.
(DOCX)
Acknowledgments
The authors of both cohorts would like to thank the children and their
parents for their continued support and enthusiasm. We greatly appreciate
the commitment they have given to the project. We would also like to
acknowledge the hard work and dedication of the study team (post-doctoral
scientists, research fellows, nurses, physiologists, technicians, and clerical
staff).
Author Contributions
Conceived and designed the experiments: AS AC AJH. Analyzed the data:
DCMB RG JG CB IB. Wrote the first draft of the manuscript: DCMB AC
AS. Wrote the paper: DCMB CB JG RG IB AS AC AJH. ICMJE criteria
for authorship read and met: DCMB CB JG RG IB AS AC AJH. Agree
with manuscript results and conclusions: DCMB CB JG RG IB AS AC
AJH. Enrolled patients: AS AC AJH. Extracted and provided ALSPAC
data for the study: RG AJH.
References
1. Wahn U (2000) What drives the allergic march? Allergy 55: 591–599.
2. Wahn U, Bergmann R, Kulig M, Forster J, Bauer CP (1997) The natural course
of sensitisation and atopic disease in infancy and childhood. Pediatr Allergy
Immunol 8: 16–20.
3. Saunes M, Oien T, Dotterud CK, Romundstad PR, Storro O, et al. (2012) Early
eczema and the risk of childhood asthma: a prospective, population-based study.
BMC Pediatr 12: 168.
4. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, et al. (2014)
Atopic dermatitis and the atopic march revisited. Allergy 69: 17–27.
5. Burgess JA, Lowe AJ, Matheson MC, Varigos G, Abramson MJ, et al. (2009)
Does eczema lead to asthma? J Asthma 46: 429–436.
6. Spergel JM (2010) Epidemiology of atopic dermatitis and atopic march in
children. Immunol Allergy Clin North Am 30: 269–280.
7. Spergel JM, Paller AS (2003) Atopic dermatitis and the atopic march. J Allergy
Clin Immunol 112 (Suppl 6): S118–S127.
8. Rhodes HL, Thomas P, Sporik R, Holgate ST, Cogswell JJ (2002) A birth cohort
study of subjects at risk of atopy: twenty-two-year follow-up of wheeze and atopic
status. Am J Respir Crit Care Med 165: 176–180.
9. Spergel JM (2010) From atopic dermatitis to asthma: the atopic march. Ann
Allergy Asthma Immunol 105: 99–106.
10. Shaker M (2014) New insights into the allergic march. Curr Opin Pediatr 26:
516–520.
11. Schneider L, Tilles S, Lio P, BoguniewiczM, Beck L, et al. (2013) Atopic dermatitis:
a practice parameter update 2012. J Allergy Clin Immunol 131: 295–9.e1-27.
12. National Collaborating Centre for Women’s and Children’s Health (2007)
Atopic eczema in children: management of atopic eczema in children from birth
up to the age of 12 years. London: National Collaborating Centre for Women’s
and Children’s Health.
13. (1998) Allergic factors associated with the development of asthma and the
influence of cetirizine in a double-blind, randomised, placebo-controlled trial:
first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy
Immunol 9: 116–124.
14. Diepgen TL (2002) Long-term treatment with cetirizine of infants with atopic
dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial
(the ETAC trial) over 18 months. Pediatr Allergy Immunol 13: 278–286.
15. Saarinen UM, Kajosaari M (1995) Breastfeeding as prophylaxis against atopic
disease: prospective follow-up study until 17 years old. Lancet 346: 1065–1069.
16. Austin JB, Kaur B, Anderson HR, Burr M, Harkins LS, et al. (1999) Hay fever,
eczema, and wheeze: a nationwide UK study (ISAAC, international study of
asthma and allergies in childhood). Arch Dis Child 81: 225–230.
17. Kurukulaaratchy RJ, Matthews S, Arshad SH (2005) Defining childhood atopic
phenotypes to investigate the association of atopic sensitization with allergic
disease. Allergy 60: 1280–1286.
18. Martin PE, Matheson MC, Gurrin L, Burgess JA, Osborne N, et al. (2011)
Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a
prospective cohort study over 4 decades. J Allergy Clin Immunol 127: 1473–1479.
19. von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindstrom CB,
et al. (2012) Eczema in early childhood is strongly associated with the development
of asthma and rhinitis in a prospective cohort. BMC Dermatol 12: 1471–5945.
20. Wuthrich B, Schmid-Grendelmeier P (2003) The atopic eczema/dermatitis
syndrome. Epidemiology, natural course, and immunology of the IgE-associated
(‘‘extrinsic’’) and the nonallergic (‘‘intrinsic’’) AEDS. J Investig Allergol Clin
Immunol 13: 1–5.
21. Kulig M, Bergmann R, Niggemann B, Burow G, Wahn U, et al. (1998)
Prediction of sensitization to inhalant allergens in childhood: evaluating family
history, atopic dermatitis and sensitization to food allergens. Clin Exp Allergy
28: 1397–1403.
22. Hopper JL, Bui QM, Erbas B, Matheson MC, Gurrin LC, et al. (2012) Does
eczema in infancy cause hay fever, asthma, or both in childhood? Insights from a
novel regression model of sibling data. J Allergy Clin Immunol 130: 1117–1122.
23. Illi S, von Mutius E, Lau S, Nickel R, Niggemann B, et al. (2001) The pattern of
atopic sensitization is associated with the development of asthma in childhood.
J Allergy Clin Immunol 108: 709–714.
24. van der Hulst AE, Klip H, Brand PL (2007) Risk of developing asthma in young
children with atopic eczema: a systematic review. J Allergy Clin Immunol 120:
565–569.
25. Williams H, Flohr C (2006) How epidemiology has challenged 3 prevailing
concepts about atopic dermatitis. J Allergy Clin Immunol 118: 209–213.
26. Barberio G, Pajno GB, Vita D, Caminiti L, Canonica GW, et al. (2008) Does a
‘reverse’ atopic march exist? Allergy 63: 1630–1632.
27. Illi S, von Mutius E, Lau S, Nickel R, Gruber C, et al. (2004) The natural course
of atopic dermatitis from birth to age 7 years and the association with asthma.
J Allergy Clin Immunol 113: 925–931.
28. Bishop CM (2013) Model-based machine learning. Philos Trans A Math Phys
Eng Sci 371: 20120222.
29. Simpson A, Tan VY, Winn J, Svensen M, Bishop CM, et al. (2010) Beyond
atopy: multiple patterns of sensitization in relation to asthma in a birth cohort
study. Am J Respir Crit Care Med 181: 1200–1206.
30. Lazic N, Roberts G, Custovic A, Belgrave D, Bishop CM, et al. (2013) Multiple
atopy phenotypes and their associations with asthma: similar findings from two
birth cohorts. Allergy 68: 764–770.
31. Prosperi MC, Belgrave D, Buchan I, Simpson A, Custovic A (2014) Challenges
in interpreting allergen microarrays in relation to clinical symptoms: a machine
learning approach. Pediatr Allergy Immunol 25: 71–79.
32. Prosperi MC, Sahiner UM, Belgrave D, Sackesen C, Buchan IE, et al. (2013)
Challenges in identifying asthma subgroups using unsupervised statistical
learning techniques. Am J Respir Crit Care Med 188: 1303–1312.
33. Colman I, Ploubidis GB, Wadsworth ME, Jones PB, Croudace TJ (2007) A
longitudinal typology of symptoms of depression and anxiety over the life course.
Biol Psychiatry 62: 1265–1271.
34. Pickles A, Bolton P,Macdonald H, Bailey A, Le Couteur A, et al. (1995) Latent-class
analysis of recurrence risks for complex phenotypes with selection and measurement
error: a twin and family history study of autism. Am J Hum Genet 57: 717–726.
35. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, et al. (2013) Cohort profile:
the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of
Parents and Children. Int J Epidemiol 42: 111–127.
36. Custovic A, Simpson BM, Murray CS, Lowe L, Woodcock A (2002) The
National Asthma Campaign Manchester Asthma and Allergy Study. Pediatr
Allergy Immunol 13 (Suppl 15): 32–37.
37. Ferris BG (1978) Epidemiology Standardization Project (American Thoracic
Society). Am Rev Respir Dis 118: 1–120.
38. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, et al. (1995) International
Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods.
Eur Respir J 8: 483–491.
39. Minka TP (2001) Expectation propagation for approximate Bayesian inference.
San Francisco (California): Morgan Kaufmann Publishers.
40. Minka T, Winn J, Guiver J, Knowles D (2010) Infer.NET, version 2.4.
Cambridge: Microsoft Research Cambridge.
41. Bishop CM (1997) Bayesian neural networks. J Braz Comp Soc 4. doi:10.1590/
S0104-65001997000200006
42. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, et al. (2013) Bayesian
data analysis, 3rd edition. Boca Raton (Florida): CRC Press.
43. Bishop CM (2006) Pattern recognition and machine learning. New York:
Springer.
44. Belgrave DC, Simpson A, Semic-Jusufagic A, Murray CS, Buchan I, et al. (2013)
Joint modeling of parentally reported and physician-confirmed wheeze identifies
children with persistent troublesome wheezing. J Allergy Clin Immunol 132:
575–583.e12.
Developmental Profiles of Eczema, Wheeze, and Rhinitis
PLOS Medicine | www.plosmedicine.org 13 October 2014 | Volume 11 | Issue 10 | e1001748
Editors’ Summary
Background. Our immune system protects us from viruses,
bacteria, and other pathogens by recognizing specific
molecules on the invader’s surface and initiating a sequence
of events that culminates in the death of the pathogen.
Sometimes, however, our immune system responds to
harmless materials (allergens such as pollen) and triggers
allergic, or atopic, symptoms. Common atopic symptoms
include eczema (transient dry itchy patches on the skin),
wheeze (high pitched whistling in the chest, a symptom of
asthma), and rhinitis (sneezing or a runny nose in the
absence of a cold or influenza). All these symptoms are very
common during childhood, but recent epidemiological
studies (examinations of the patterns and causes of diseases
in a population) have revealed age-related changes in the
proportions of children affected by each symptom. So, for
example, eczema is more common in infants than in school-
age children. These findings have led to the idea of ‘‘atopic
march,’’ a natural progression of symptoms within individual
children that starts with eczema, then progresses to wheeze
and finally rhinitis.
Why Was This Study Done? The concept of atopic march
has led to the initiation of studies that aim to prevent the
development of asthma in children who are thought to be at
risk of asthma because they have eczema. Moreover, some
guidelines recommend that clinicians tell parents that
children with eczema may later develop asthma or rhinitis.
However, because of the design of the epidemiological
studies that support the concept of atopic march, children
with eczema who later develop wheeze and rhinitis may
actually belong to a distinct subgroup of children, rather
than representing the typical progression of atopic diseases.
It is important to know whether atopic march adequately
describes the natural history of atopic diseases during
childhood to avoid the imposition of unnecessary strategies
on children with eczema to prevent asthma. Here, the
researchers use machine learning techniques to model the
developmental profiles of eczema, wheeze, and rhinitis
during childhood in two large population-based birth
cohorts by taking into account time-related (longitudinal)
changes in symptoms within individuals. Machine learning is
a data-driven approach that identifies structure within the
data (for example, a typical progression of symptoms) using
unsupervised learning of latent variables (variables that are
not directly measured but are inferred from other observable
characteristics).
What Did the Researchers Do and Find? The researchers
used data from two UK birth cohorts—the Avon Longitudi-
nal Study of Parents and Children (ALSPAC) and the
Manchester Asthma and Allergy Study (MAAS)—for their
study (9,801 children in total). Both studies enrolled children
at birth and monitored their subsequent health at regular
review clinics. At each review clinic, information about
eczema, wheeze, and rhinitis was collected from the parents
using validated questionnaires. The researchers then used
these data and machine learning methods to identify groups
of children with similar patterns of onset of eczema, wheeze,
and rhinitis over the first 11 years of life. Using a type of
statistical model called a latent disease profile model, the
researchers found that the data were best described by eight
latent classes—no disease (51.3% of the children), atopic
march (3.1%), persistent eczema and wheeze (2.7%), persis-
tent eczema with later-onset rhinitis (4.7%), persistent
wheeze with later-onset rhinitis (5.7%), transient wheeze
(7.7%), eczema only (15.3%), and rhinitis only (9.6%).
What Do These Findings Mean? These findings show
that, in two large UK birth cohorts, the developmental
profiles of eczema, wheeze, and rhinitis were heterogeneous.
Most notably, the progression of symptoms fitted the profile
of atopic march in fewer than 7% of children with symptoms.
The researchers acknowledge that their study has some
limitations. For example, small differences in the wording of
the questions used to gather information from parents about
their children’s symptoms in the two cohorts may have
slightly affected the findings. However, based on their
findings, the researchers propose that, because eczema,
wheeze, and rhinitis are common, these symptoms often
coexist in individuals, but as independent entities rather than
as a linked progression of symptoms. Thus, using eczema as
an indicator of subsequent asthma risk and assigning
‘‘preventative’’ measures to children with eczema is flawed.
Importantly, clinicians need to understand the heterogeneity
of patterns of atopic diseases in children and to communi-
cate this variability to parents when advising them about the
development and resolution of atopic symptoms in their
children.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001748.
N The UK National Health Service Choices website
provides information about eczema (including personal
stories), asthma (including personal stories), and rhinitis
N The US National Institute of Allergy and Infectious
Diseases provides information about atopic diseases
N The UK not-for-profit organization Allergy UK provides
information about atopic diseases and a description of
the atopic march
N MedlinePlus encyclopedia has pages on eczema,
wheezing, and rhinitis (in English and Spanish)
N MedlinePlus provides links to further resources about
allergies, eczema, and asthma (in English and Spanish)
N Information about ALSPAC and MAAS is available
N Wikipedia has pages on machine learning and latent
disease profile models (note that Wikipedia is a free
online encyclopedia that anyone can edit; available in
several languages)
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